See more : American Environmental, Inc. (MZPS) Income Statement Analysis – Financial Results
Complete financial analysis of ST Pharm Co.,Ltd. (237690.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ST Pharm Co.,Ltd., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Picton Property Income Limited (PCTN.L) Income Statement Analysis – Financial Results
- Medacta Group SA (MOVE.SW) Income Statement Analysis – Financial Results
- Kaynes Technology India Limited (KAYNES.BO) Income Statement Analysis – Financial Results
- Impact Coatings AB (publ) (IMPC.ST) Income Statement Analysis – Financial Results
- Shanghai Hugong Electric Group Co.,Ltd. (603131.SS) Income Statement Analysis – Financial Results
ST Pharm Co.,Ltd. (237690.KQ)
About ST Pharm Co.,Ltd.
ST Pharm Co. Ltd., a contract development manufacturing organization, provides products for pharmaceutical and non-pharmaceutical area in South Korea. The company offers chemistry manufacturing control (CMC) services, which includes analytical method development; in-house reference standard testing; analytical method qualification/validation; analytical characterization; and CMC documentation. It also provides oligonucleotide based products, such as antisense, siRNA, miRNA, aptamer, CpG, decoy, and other products; and monomer/phosphoramidite. In addition, the company offers generic APIs for anti-cancer, anti-coagulant, anti-fungal, anti-hyperlipidemia, anti-hypertensive, anti-tuberculosis, asthma, COPD, cough suppressant, diabetes mellitus, epilepsy, hepatitis B, and erectile dysfunction medicines, as well as MRI contrast agents. Further, it provides 2nd battery, electronic materials, and polymer catalysts. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 and is based in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 284.99B | 249.32B | 165.64B | 124.11B | 93.26B | 97.74B | 202.80B | 200.36B | 138.05B |
| Cost of Revenue | 178.36B | 166.04B | 111.73B | 107.55B | 96.05B | 95.68B | 123.66B | 107.44B | 86.93B |
| Gross Profit | 106.63B | 83.28B | 53.91B | 16.56B | -2.80B | 2.06B | 79.14B | 92.92B | 51.12B |
| Gross Profit Ratio | 37.41% | 33.40% | 32.55% | 13.34% | -3.00% | 2.11% | 39.02% | 46.38% | 37.03% |
| Research & Development | 30.85B | 25.15B | 17.25B | 12.41B | 14.41B | 8.23B | 9.16B | 8.58B | 10.34B |
| General & Administrative | 4.99B | 6.02B | 3.40B | 2.70B | 255.88M | 192.99M | 168.42M | 122.78M | 126.99M |
| Selling & Marketing | 4.79B | 3.18B | 2.83B | 1.97B | 1.95B | 2.99B | 2.21B | 2.31B | 2.27B |
| SG&A | 44.75B | 40.28B | 31.09B | 22.97B | 9.49B | 9.47B | 8.15B | 6.41B | 6.20B |
| Other Expenses | 0.00 | 725.39M | 87.79M | 444.52M | 0.00 | 0.00 | 0.00 | -352.32M | 0.00 |
| Operating Expenses | 75.59B | 65.43B | 48.34B | 35.38B | 23.91B | 17.71B | 17.31B | 15.34B | 11.31B |
| Cost & Expenses | 253.96B | 231.47B | 160.06B | 142.93B | 119.96B | 113.38B | 140.97B | 122.78B | 98.24B |
| Interest Income | 2.44B | 1.24B | 939.37M | 618.04M | 1.26B | 1.52B | 1.20B | 610.57M | 4.21B |
| Interest Expense | 6.11B | 2.87B | 5.16B | 644.58M | 78.87M | 970.00 | 63.61M | 1.24B | 4.41B |
| Depreciation & Amortization | 23.03B | 17.60B | 14.41B | 14.07B | 11.19B | 9.23B | 11.57B | 10.79B | 6.16B |
| EBITDA | 52.49B | 39.71B | 20.83B | -2.11B | -13.71B | -6.42B | 70.88B | 92.53B | 46.14B |
| EBITDA Ratio | 18.42% | 14.22% | 12.07% | -3.83% | -16.64% | -6.57% | 36.19% | 44.10% | 29.43% |
| Operating Income | 31.04B | 17.85B | 5.58B | -18.82B | -26.70B | -15.65B | 61.83B | 77.58B | 34.47B |
| Operating Income Ratio | 10.89% | 7.16% | 3.37% | -15.16% | -28.63% | -16.01% | 30.49% | 38.72% | 24.97% |
| Total Other Income/Expenses | -7.68B | 1.39B | -4.32B | 1.99B | 1.73B | 2.26B | -2.59B | 2.91B | 1.13B |
| Income Before Tax | 23.35B | 19.24B | 1.26B | -16.82B | -24.97B | -13.39B | 59.24B | 80.50B | 35.60B |
| Income Before Tax Ratio | 8.19% | 7.72% | 0.76% | -13.56% | -26.78% | -13.70% | 29.21% | 40.18% | 25.79% |
| Income Tax Expense | 5.83B | 1.72B | -2.12B | -3.67B | -6.44B | -4.12B | 14.25B | 19.07B | 10.41B |
| Net Income | 19.58B | 18.00B | 3.31B | -12.15B | -18.53B | -9.27B | 45.00B | 61.43B | 25.19B |
| Net Income Ratio | 6.87% | 7.22% | 2.00% | -9.79% | -19.87% | -9.48% | 22.19% | 30.66% | 18.25% |
| EPS | 1.04K | 957.00 | 177.50 | -651.11 | -993.18 | -496.78 | 2.42K | 3.86K | 2.01K |
| EPS Diluted | 1.04K | 957.00 | 177.50 | -651.11 | -993.18 | -496.78 | 2.41K | 3.74K | 2.01K |
| Weighted Avg Shares Out | 18.81M | 18.81M | 18.66M | 18.66M | 18.66M | 18.66M | 18.58M | 15.91M | 12.53M |
| Weighted Avg Shares Out (Dil) | 18.81M | 18.81M | 18.66M | 18.66M | 18.66M | 18.66M | 18.68M | 16.43M | 12.53M |
Source: https://incomestatements.info
Category: Stock Reports